Trident Lifeline last traded at ₹381.25 (2026-10-13). Over the past month the stock moved +28.2%, three months the stock moved +52.6%, year the stock moved +27.9%. Its closing range over 52 weeks is ₹240.80 – ₹410.00, with the latest close 7.0% below the high.
Closing prices up to 2026-10-13.
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products[1]
Business Overview:[1] TLL is a Surat-based pharmaceutical and healthcare-products company. It began as an export-oriented formulations company using third-party and loan-licence manufacturing. It is now evolving into a vertically integrated healthcare-manufacturing platform through its own and subsidiary facilities.
In the latest quarter (Jun 2026), Trident Lifeline reported sales of ₹33.72 crore (+42.8%) and net profit of ₹5.07 crore (+82.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 33.72 | 8.52 | 25.27 | 5.07 | 4.22 |
| Mar 2026 | 49.95 | 10.99 | 22.00 | 6.80 | 5.64 |
| Dec 2025 | 25.71 | 5.09 | 19.80 | 4.64 | 3.60 |
| Sep 2025 | 31.34 | 6.86 | 21.89 | 5.09 | 4.27 |
| Jun 2025 | 23.61 | 5.17 | 21.90 | 2.78 | 2.66 |
| Mar 2025 | 34.01 | 8.54 | 25.11 | 6.14 | 6.15 |
| Dec 2024 | 11.83 | 4.07 | 34.40 | 2.56 | 2.43 |
| Sep 2024 | 15.45 | 4.05 | 26.21 | 2.80 | 2.69 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +78.8% | +66.9% | +77.8% | +79.5% | +102.8% | +117.3% | +46.9% | +42.8% |
| Operating profit growth | +130.1% | +184.6% | +261.9% | +107.6% | +69.4% | +25.1% | +28.7% | +64.8% |
| Net profit growth | +100.0% | +143.8% | +276.7% | +73.7% | +81.8% | +81.2% | +10.7% | +82.4% |
| EPS growth | +120.5% | +158.5% | +247.5% | +33.7% | +58.7% | +48.1% | -8.3% | +58.6% |
| OPM % | 26.2% | 34.4% | 25.1% | 21.9% | 21.9% | 19.8% | 22.0% | 25.3% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Trident Lifeline reported sales of ₹129.00 crore (+48.3%) and net profit of ₹19.00 crore (+90.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 129.00 | 28.00 | 22.00 | 19.00 | 15.96 |
| Mar 2025 | 87.00 | 15.00 | 17.00 | 10.00 | 10.22 |
| Mar 2024 | 45.00 | 8.00 | 18.00 | 6.00 | 5.51 |
| Mar 2023 | 32.00 | 6.00 | 20.00 | 6.00 | 5.24 |
| Mar 2022 | 22.00 | 3.00 | 12.00 | 4.00 | 4.94 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales growth | +45.5% | +40.6% | +93.3% | +48.3% |
| Operating profit growth | +100.0% | +33.3% | +87.5% | +86.7% |
| Net profit growth | +50.0% | +0.0% | +66.7% | +90.0% |
| EPS growth | +6.1% | +5.2% | +85.5% | +56.2% |
| OPM % | 20.0% | 18.0% | 17.0% | 22.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Trident Lifeline.
Get Free AI Stock Analysis FREE →No recent news available for Trident Lifeline.
Trident Lifeline shares were last quoted at ₹381.25 (+3.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Trident Lifeline has a price-to-earnings (P/E) ratio of 22.89 and a price-to-book (P/B) ratio of 4.74. The industry P/E is 53.33.
The 52-week high of Trident Lifeline is ₹421.00 and the 52-week low is ₹229.95.
The market capitalisation of Trident Lifeline is about ₹481.00 crore.
In the latest quarter (Jun 2026), Trident Lifeline reported sales of ₹33.72 crore (+42.8%) and net profit of ₹5.07 crore (+82.4%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Trident Lifeline has a 3-year ROE of 20.00%, 3-year profit growth of 47.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 62.59% of Trident Lifeline.
Trident Lifeline belongs to the Food & Drug Retailing sector.